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A randomized trial of iron deficiency testing strategies in hemo- sively high epoetin doses [1–3]. As a result of this, diag-
dialysis patients. nostic tests for iron deficiency are performed on a regular
Background. Diagnosis of iron deficiency in hemodialysis pa-
basis, generally every three months [4]. Testing is impor-tients is limited by the inaccuracy of commonly used tests.
tant not only to detect iron deficiency, but additionally toReticulocyte hemoglobin content (CHr) is a test that has shown
promise for improved diagnosis in preliminary studies. The avoid overtreatment with intravenous iron drugs, agents
purpose of this study was to compare iron management guided that may occasionally cause severe adverse reactions
by serum ferritin and transferrin saturation to management
[5–8]. Testing must accurately detect iron deficient pa-guided by CHr.
tients who require intensified iron treatment while ex-Methods. A total of 157 hemodialysis patients from three cen-
ters were randomized to iron management based on (group 1) cluding patients who are iron replete. Ideally, the results
serum ferritin and transferrin saturation, or (group 2) CHr. of iron monitoring should allow for consistent mainte-Patients were followed for six months. Treatment with intrave-
nance of the target hemoglobin level, while avoiding ex-nous iron dextran, 100 mg for 10 consecutive treatments was
initiated if (group 1) serum ferritin 100 ng/mL or transferrin cessively high epoetin doses and unnecessary intrave-
saturation 20%, or (group 2) CHr 29 pg. nous iron use while allowing these goals to be achieved
Results. There was no significant difference between groups
without excessive cost.in the final mean hematocrit or epoetin dose. The mean weekly
Tests assessing the iron status in general use in Ameri-dose of iron dextran was 47.7  35.5 mg in group 1 compared
to 22.9  20.5 mg in group 2 (P  0.02). The final mean serum can dialysis units are serum ferritin and transferrin satu-
ferritin was 399.5 247.6 ng/mL in group 1 compared to 304.7 ration [4]. Both tests have limited accuracy when used
290.6 ng/mL in group 2 (P  0.05). There was no significant
in hemodialysis patients. Previous studies have demon-difference in final TSAT or CHr. Coefficient of variation was
strated the serum ferritin at levels of 100 to 200 ng/mL tosignificantly lower for CHr than serum ferritin and transferrin
saturation (3.4% vs. 43.6% and 39.5%, respectively). have a sensitivity of only 41 to 48%, and a specificity of 75
Conclusions. CHr is a markedly more stable analyte than to 100% for detecting iron deficiency [9, 10]. Using higherserum ferritin or transferrin saturation, and iron management
cutoff levels of serum ferritin would improve sensitivity,based on CHr results in similar hematocrit and epoetin dosing
while significantly reducing IV iron exposure. but at the cost of a significant drop off in specificity. A
transferrin saturation of 20 to 21% has sensitivity of 81
to 88%, but with a specificity of only 63% [9, 10]. Decreas-
Treatment of iron deficiency is an important compo- ing the cutoff value would improve the specificity, but
nent of care for patients on hemodialysis. Failure to rec- in this case would incur a significant loss of sensitivity.
ognize and adequately treat iron deficiency leads to sub- Reticulocyte hemoglobin content (CHr) is a test of iron
optimized anemia therapy, with difficulty reaching target status that potentially may be more accurate [11, 12].
hematocrit or hemoglobin levels or the need for exces- Initial studies in hemodialysis patients have suggested
excellent utility for this test as a guide to iron manage-
1 See Editorial by Besarab, p. 2412. ment [13–15]. Our group found a sensitivity of 100%
and specificity of 80% among a group of 32 hemodialysis
Key words: serum ferritin, transferrin saturation, reticulocyte hemoglo-
patients [13]. These promising results made clear thebin content, hematocrit, epoetin dose, anemia.
need for a more rigorous evaluation of CHr. The purpose
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METHODS cation of the hemoglobin content of each reticulocyte,
reported in picograms.Patients
One hundred fifty-seven hemodialysis patients from Statistical analysis
three dialysis centers were enrolled. Participating centers Primary outcome measures were hematocrit, epoetin
were Winthrop-University Hospital Dialysis at Bethpage dose, iron dose requirements, serum ferritin, transferrin
(B:WUHD), a 12-station suburban unit, WUHD at Min- saturation and CHr. The Student t test was used to ana-
eola (M:WUHD), a 35-station suburban unit, and Brook- lyze differences between baseline and end of study, and
dale Medical Center Dialysis (B), a 28-station urban differences between groups for continuous variables.
unit. Eligibility criteria included age older than 18 years, Log transformation was used for non-normally distrib-
hemodialysis treatment for three months or more, use uted data. Fisher’s Exact Test was used to compare
of epoetin for three months or greater with no change in groups for categorical variables. Variation in test results
dose for four weeks, no blood transfusion in the previous was expressed as coefficient of variation. Each patient’s
three months, no intravenous iron treatment in the previ- standard deviation of test results was squared to obtain
ous month, no hematologic disease other than anemia, individual variances. The square root of the pooled vari-
and no hospitalization or significant bleeding episodes ances was divided by the pooled mean of all test results
(requiring hospitalization or blood transfusion) in the to yield the coefficient of variation for each test. For
previous three months. calculation of positive predictive value, the number of
Patients were assigned at random to one of two study patients with a positive response to intravenous iron
groups: group 1, iron management based on serum ferri- treatment was divided by the number predicted by the
tin and transferrin saturation; and group 2, iron manage- testing to need iron treatment. A positive response was
defined as an increase in 3 basis points in Hct and/or ament based on CHr.
decrease of 15% in weekly epoetin dose in the eightEach patient was followed for six months. Hemoglobin
weeks after treatment with intravenous iron. All resultsand hematocrit (Hct) were measured every two weeks,
are reported as mean  standard deviation. P valuesand the dose of epoetin was adjusted to maintain hema-
of  0.05 were considered statistically significant.tocrit between 33 and 36%. The same dosing protocol
was used at all centers, and personnel independent of
the study and unaware of patients’ randomization made RESULTS
all epoetin-dosing changes. The protocol called for 25%
A total of 157 patients were enrolled and random-dose reductions for Hct 36% and holding doses if Hct
ized, of whom 19 were withdrawn during the study pe-
40%, or 50% dose increases for Hct 33%. Epoetin re-
riod. Withdrawals were due to prolonged hospitalizationsponse was characterized using an epoetin response in-
(N  8), bleeding requiring blood transfusion (3), trans-dex (ERI) calculated as Hct/weekly epoetin dose*100.
plant (1), withdrawal of consent (1), protocol violationHigher values are consistent with greater responsiveness
(4), and death (2). Patients completing the study were
to epoetin treatment. Serum ferritin, transferrin saturation
from WUHD-Mineola (N  74), Brookdale (51), and
and CHr were measured every four weeks. Intravenous
WUHD-Bethpage (13). Patient characteristics are re-
iron dextran, 100 mg for 10 consecutive hemodialysis ported in Table 1. Specifically, factors other than iron
treatments, was initiated if (in group 1) serum ferritin that could impact on anemia management, such as dial-
100 ng/mL or transferrin saturation 20%; or (in group ysis dose (Kt/V), urea reduction ratio (URR), serum
2) CHr 29 pg. aluminum and parathyroid hormone level (PTH) were
Intravenous iron was only administered if the patient not significantly different between the groups at baseline.
met the above criteria. More than one course could be The mean Hct remained in the targeted range (33 to
administered during the six months of study. Intraven- 36%) throughout the study period in both groups (Table
ous iron was not administered if serum ferritin was 2). There was no significant difference between the two
800 ng/mL or transferrin saturation 50%. groups as to mean Hct at any time point. The mean
epoetin dose requirement trended lower for both groups,
Iron status tests however, the results did not reach statistical significance
Serum ferritin and transferrin saturation were deter- (Table 2). Epoetin dose adjustments were required at a
mined every four weeks by standard methods. Reticulo- mean of 2.8  2.0 times per patient. The ERI was not
cyte hemoglobin content (CHr) was determined using significantly different between the two groups at the end
the ADVIA 120 hematology system (Bayer Corpora- of the study (group 1, 0.30 vs. group 2, 0.32; P  NS).
tion, Tarrytown, NY, USA). CHr is derived from the Of 74 patients in group 1, serum ferritin and transferrin
simultaneous measurement of volume and hemoglobin saturation were tested 419 times, resulting in 59 (79.7%)
subjects receiving 104 courses of intravenous iron. Inconcentration in reticulocytes. The CHr value is an indi-
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Table 2. Hematocrit and weekly epoetin dose by treatment groupTable 1. Patient characteristics
Group 1 Group 2 Week BL 8 16 24 28
(N74) (N64)
Group 1 35.4 35 34.6 34.7 35
Hct % (3.4) (3.3) (3.4) (3.3) (3.4)Center (B:WUHD-M:WUHD-B) 26:43:5 25:31:8
Age years 60.514.5 60.014.6 Group 2 35.8 34.6 35.5 35.4 35.3
Hct % (3.5) (3.4) (3.3) (3.5) (3.2)Percent men 51 56
Months on dialysis 33.432.7 38.139.4 Group 1 12232 12077 12100 11902 11772
EPO U/week (11029) (11444) (11029) (11320) (11780)Ethnicity:
Causcasian 36 28 Group 2 12237 12200 11300 10933 10949
EPO U/week (12001) (12049) (11785) (12095) (12154)African-American 31 30
Hipanic 5 4 Results in parentheses are standard deviation. Abbreviations are: BL, baseline;
Other 2 2 Hct, hematocrit; EPO, erythropoietin.
Cause of ESRD:
Diabetes 28 23
Hypertension 19 16
CGN 11 8
PCKD 8 4 final 304.7  290.6 ng/mL (P  0.05 comparing final
Other 8 13 group 1 vs. final group 2). The mean transferrin satura-Hct % 35.43.4 35.83.5
tion was not significantly different between the groups atEpoetin dose U/weeks 1223211029 1223712001
Serum ferritin ng/mL 229.6178.8 251.7231.3 baseline (Table 4). At study conclusion, mean transferrin
TSAT % 24.712.7 22.311.7 saturation had increased significantly in group 1 to 29.4CHr pg 31.11.8 30.81.7
17.8% compared to no significant change in group 2, finalSerum aluminum lg/L 16.811.3 15.210.1
Kt/V 1.690.31 1.660.30 25.8  16.6%. Mean CHr was not significantly different
URR % 74.25.6 75.05.5 between the groups at baseline, and did not change sig-PTH pg/mL 192.7166.4 183.4170.1
nificantly in either group throughout the study, final
Abbreviations are: ESRD, end-stage renal disease; CGN, chronic glomerulo-
31.1  1.8 pg group 1, and 30.8  1.8 group 2 (P  NS).nephritis; PKD, polycystic kidney disease; TSAT, transferrin saturation; Hct,
hematocrit; CHr, reticulolyte hemoglobin content; Kt/V, dialysis dose; URR, The mean reticulocyte hemoglobin content (CHr)
urea reduction ratio; PTH, parathyroid hormone.
among all samples tested was 31.0  2.4 pg with values
ranging from 20.2 pg to 40.9 pg (Fig. 2). The reticulocyte
response to treatment with intravenous iron in a single
patient is depicted in Figure 3. In this patient, the meangroup 2, there were 64 patients in whom CHr was tested
CHr value at the baseline was 24.6 pg. By two weeks after369 times, resulting in 27 (42.1%) patients receiving 42
treatment with intravenous iron, the mean hemoglobincourses of intravenous iron (P  0.05 compared to
content of the patient’s reticulocytes increased fromgroup 1). The mean weekly dose of intravenous iron
dextran was 47.7 35.5 mg in group 1 patients compared 24.6 pg to 28.4 pg. The distribution width of CHr nar-
to 22.920.5 mg in group 2 (P  0.02; Fig. 1 and Table rowed significantly, indicating the growth of a more sta-
3). The predictive value of serum ferritin 100 ng/mL ble, homogeneous population of cells with improving
or transferrin saturation 20% in group 1 for a positive iron carriage. The total reticulocyte count and Hct had
response to intravenous iron, was 43.8%, compared to not yet increased. By four weeks after iron treatment, the
72.7% for CHr 29 pg in group 2. The stimulus for iron CHr had normalized at 31.8 pg, and both the reticulocyte
treatment in group 1 was transferrin saturation 20% count, and Hct rose significantly. Additionally, the hemo-
alone in 67.3% of the 104 intravenous iron courses, se- globin content of the mature red cell population, as indi-
rum ferritin100 ng/mL alone in 19.2% and both param- cated by the CH value, rose significantly at four weeks.
eters being low in 13.5% of intravenous iron courses. Of Comparison of test variability was measured longitudi-
the 104 intravenous iron courses in group 1, CHr was nally for the three iron tests and is reported as coefficient
29 pg prior to the iron course in 22% of cases. In of variation (%CV). Reticulocyte hemoglobin content
contrast, in group 2, intravenous iron courses by protocol (CHr) was found to have significantly less variation than
could only be generated by CHr 29 pg. In fact, of the the other tests, with CV of 3.4% compared to serum fer-
42 courses of intravenous iron generated by CHr 29 ritin of 43.6% and transferrin saturation of 39.5% (Fig.
pg in group 2, the serum ferritin was less than 100 ng/mL 4). Recalculation of CV, excluding post-intravenous iron
in 16 (38%), and transferrin saturation was less than treatment results, yielded 2.6% for CHr, compared to
20% in 30 (71.4%) iron courses. serum ferritin at 24.5% and transferrin saturation at
The mean serum ferritin at baseline was not signifi- 27.2%.
cantly different between the groups (229.6 178.8 ng/mL
vs. 251.7  231.3 ng/mL, groups 1 and 2, respectively;
DISCUSSIONP  NS; Table 4). At study conclusion mean serum
The major findings of the current study are that (1)ferritin increased significantly in group 1 to 399.5 
247.6 ng/mL, compared to no significant change in group 2, CHr had much less variability than either serum ferritin
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Fig. 1. Intravenous iron dextran weekly dose
requirements by study group. (Reproduction
of this figure in color was made possible by
Bayer Diagnostics, Inc.)
Fig. 2. Distribution of reticulocyte hemoglobin content (CHr) values
Fig. 4. Coefficient of variation (CV) for the three tests. Blue barsamong all subjects. (Reproduction of this figure in color was made
represent all tests, purple bars represent CV excluding tests performedpossible by Bayer Diagnostics, Inc.)
after intravenous iron treatment. (Reproduction of this figure in color
was made possible by Bayer Diagnostics, Inc.)
requirements; and (3) iron testing by either method on
a monthly basis facilitated attaining a high-end National
Kidney Foundation–Dialysis Outcomes Quality Initia-
tive (NKF/DOQI) target hematocrit values with stable
epoetin dose requirements (there was a non-significant
trend to lower dose requirements for both groups).
The primary goal of iron supplementation in hemodi-
alysis patients is to support epoetin therapy, enabling
the consistent achievement of a hematocrit of 33 to 36%.
The NKF/DOQI Guidelines for Anemia Management
stress that most hemodialysis patients will require regular
treatment with intravenous iron to achieve the target
Fig. 3. Histograms of reticulocyte hemoglobin content (CHr). Results hematocrit [4]. The guidelines recommend that dosing
are from a single patient at baseline, and then 2 and 4 weeks after with intravenous iron be based on maintaining serum
intravenous iron treatment. As hematocrit (Hct) and CHr improve, the
ferritin 100 ng/mL and transferrin saturation 20%.population of reticulocytes matures and normalizes compared to mature
cells. (Reproduction of this figure in color was made possible by Bayer Both tests, however, are somewhat inaccurate measures
Diagnostics, Inc.) of iron status. Sensitivity, the ability to detect iron defi-
ciency, is quite low for serum ferritin: 41 to 48% at a
test level of 100 to 200 ng/mL [9, 10]. It is readily apparent
why this is so. Serum ferritin is a potent positive acuteor transferrin saturation; (2) iron management guided
phase reactant, and a variety of causes independent ofby CHr led to less use of intravenous iron compared to
iron status may markedly raise its value [16–18]. A highmanagement guided by serum ferritin and TSAT but was
without any detrimental effect on hematocrit or epoetin serum ferritin level in a dialysis patient may reflect iron
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Table 4. Iron parameters by patient groupTable 3. Iron testing and resulting iron treatment by study group
Group 1 Group 2 Serum ferritin Transferrin
ng/mL saturation % CHr pg(N74) (N64) P value
Baseline Final Baseline Final Baseline FinalNumber of tests of primary
parameter (Group 1–TSAT,
Group 1 (SD) 229.6 399.5a 24.7 29.4a 31.1 32.1serum ferritin, Group 2–CHr) 419 369
(178.8) (247.6) (12.7) (17.8) (1.8) (1.8)Number of patients in whom 0.05
Group 2 (SD) 251.7 304.7 22.3 25.8 30.8 30.8testing triggered a course 59 27
(231.3) (290.6) (11.7) (16.6) (1.7) (1.8)of IV iron 79.7% 42.1%
P value NS 0.05 NS 0.04 NS NSNumber of courses of IV 0.05
iron triggered 104 42 a P  0.05 final compared to baseline
Mean weekly dose of IV 0.02
iron 47.735.5 22.920.5
Positive predictive value of
testing schema 43.8% 72.7%
changes in CHr over time correlated with changes in
IV is intravenous.
hemoglobin and hematocrit levels. Eighty-two percent
of iron deficient patients responded with an increase in
CHr of 2 pg when treated with intravenous iron [14].
Bhandari et al studied 22 hemodialysis patients with ini-sufficiency, but it is equally likely to be driven by some
tial serum ferritin 60 ng/mL, and found that CHr roseother stimulus. Iron deficiency may still be present, and
after intravenous iron treatment. The authors concludedthe diagnosis missed. Specificity, the ability to exclude
that CHr improved monitoring of response to intraven-patients without iron deficiency, is adequate for serum
ous iron therapy and helped identify patients with func-ferritin, with values between 75 and 100% [9, 10]. Trans-
tional iron deficiency [15]. More recently Cullen et al stud-ferrin saturation is probably a more accurate measure,
ied CHr in 36 hemodialysis patients, and found it to bewith sensitivity between 81 and 88% but with a poor spe-
superior to percentage hypochromic red blood cells, a testcificity of 63% [9, 10]. Calculated as serum iron divided
used frequently in Europe [23]. The percentage of hypo-by total iron binding capacity, transferrin saturation re-
chromic cells indicates a subpopulation of mature redflects the quantity of iron in circulation [19]. In epoetin
blood cells that demonstrates evidence of insufficient iron.treated patients, where superphysiologic bursts of red
We have found CHr to be a far more stable test thancell production lead to rapid fluxes in serum iron concen-
transferrin saturation or serum ferritin. The coefficienttration, transferrin saturation may poorly reflect iron suf-
of variation for CHr was on the order of 90% lower thanficiency [9, 10]. A low value may reflect iron deficiency,
for the other tests. The high level of variability for serumor may simply be a reflection of intense erythropoiesis
ferritin and transferrin saturation explains an importantwith dysequilibrium between iron storage, circulation
problem in the current approach to iron testing in hemo-and the erythron. Taken together, these considerations
dialysis patients. Recommendations for iron treatmenthelp explain why nephrologists are often faced with the
by NKF-DOQI call for intensified intravenous iron treat-dilemma of transferrin saturation concentrations that in-
ment if either test has a low result. Because of the ex-dicate iron deficiency at the same time as the serum
treme variability of the tests, however, it is probable thatferritin is high, raising concern of iron overload.
in any given testing cycle one of the two tests will be low.Reticulocyte hemoglobin content (CHr) has the po-
This is likely to lead to unnecessary treatment of patientstential to be a more accurate test of iron status in hemodi-
without iron deficiency, and excessive use of intravenousalysis patients. Recently, this test was reviewed in depth
iron. In fact, that is exactly what we found, that ironby Brugnara and colleagues [20]. The CHr test is a direct
management based on these tests led to a 113% greatermeasure of iron sufficiency at the level of the reticulo-
dosing for intravenous iron compared to CHr, with nocyte, the first circulating form of erythrocytes [20, 21].
benefit in terms of hematocrit or epoetin requirement.In epoetin treated patients, a direct measure of iron
We expect that iron management based on CHr wouldstatus has a distinct advantage compared to indirect mea-
reduce the overall cost of iron management because ofsures such as serum ferritin or transferrin saturation.
the reduced intravenous iron requirements. Patients man-Because reticulocytes only remain in circulation for ap-
aged by CHr (group 2) required 25 mg less per week ofproximately 24 hours [22], CHr is a “snapshot” of iron
intravenous iron compared to patients in whom ironstatus, informing about immediate iron sufficiency. The
treatment was guided by serum ferritin and transferrintest has been studied in hemodialysis patients, and sev-
saturation. More important than financial savings is theeral reports have been published (13–15). In an initial
reduced exposure of patients to the potentially harmfulevaluation of CHr in 32 hemodialysis patients, we found
effects of intravenous iron. Risks of treatment such asthe sensitivity and specificity to detect iron deficiency to
tissue and vascular oxidation have not been extensivelybe 100% and 80% respectively [13]. Mittman et al [14]
studied CHr in 364 hemodialysis patients, and found that studied [24], but have the potential to be clinically rele-
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3. Eschbach JW, Adamson JW: Guidelines for recombinant humanvant. As such, it is best to avoid unnecessary exposure
erythropoietin therapy. Am J Kidney Dis 14(2 Suppl 1):2–8, 1989
to excessive iron treatment. 4. NKF-DOQI clinical practice guidelines for the treatment of anemia
of chronic renal failure. National Kidney Foundation–Dialysis Out-The cutoff level for CHr that we chose to guide treat-
comes Quality Initiative. Am J Kidney Dis 30(4 Suppl 3):S192–ment was 29 pg. Our previous study using the semi-
S240, 1997
automated CHr assay on the H*3 hematology analyzer 5. Faich G, Strobos J: Sodium ferric gluconate complex in sucrose:
Safer intravenous iron therapy than iron dextrans. Am J Kidney(Bayer Corporation) used a value of 26 pg [13]. The
Dis 33:464–470, 1999present study used the ADVIA120 system (Bayer Cor-
6. Freter S, Davidman M, Lipman M, Bercovitch D: Pulmonary
poration), which utilizes an automated assay for the CHr. edema: Atypical anaphylactoid reaction to intravenous iron dex-
tran. Am J Nephrol 17:477–479, 1997Using a CHr cutoff value other than 29 pg to guide
7. Fishbane S, Ungureanu VD, Maesaka JK, et al: The safety oftreatment would lead to different effects on anemia treat-
intravenous iron dextran in hemodialysis patients. Am J Kidney
ment. For example, if the cutoff value was raised to Dis 28:529–534, 1996
8. Hamstra RD, Block MH, Schocket AL: Intravenous iron dextran30 pg, more patients would be treated with intravenous
in clinical medicine. JAMA 243:1726–1731, 1980iron, reducing some of the benefit of lower iron costs
9. Kalantar-Zadeh K, Hoffken B, Wunsch H, et al: Diagnosis of
and risk exposure. On the other hand, because of the iron deficiency anemia in renal failure patients during the post-
erythropoietin era. Am J Kidney Dis 26:292–299, 1995greater accuracy of CHr compared to serum ferritin and
10. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK: The evalua-transferrin saturation, iron treatment would be more
tion of iron status in hemodialysis patients. J Am Soc Nephrol 7:
focused on patients with true iron deficiency. As a result, 2654–2657, 1996
11. Brugnara C, Zurakowski D, DiCanzio J, et al: Reticulocyte he-there might be benefit in terms of achieving the target
moglobin content to diagnose iron deficiency in children. JAMAhematocrit with a reduced dosing requirement for epoe-
281:2225–2230, 1999
tin. This would be a useful subject for further study. 12. Brugnara C, Laufer MR, Friedman AJ, et al: Reticulocyte hemo-
globin content (CHr): Early indicator of iron deficiency and re-In conclusion, we have found that iron management
sponse to therapy. Blood 83:3100–3101, 1994based on CHr is simple and practical to perform. The
13. Fishbane S, Galgano C, Langley RC, et al: Reticulocyte hemoglo-
test may be performed during routine blood testing for bin content in the evaluation of iron status of hemodialysis patients.
Kidney Int 52:217–222, 1997hemoglobin and hematocrit, by the same hematology
14. Mittman N, Sreedhara R, Mushnick R, et al: Reticulocyte hemo-analyzer, at little incremental cost. Compared to manage-
globin content predicts functional iron deficiency in hemodialysis
ment based on serum ferritin and transferrin saturation, patients receiving rHuEPO. Am J Kidney Dis 30:912–922, 1997
15. Bhandari S, Norfolk D, Brownjohn A, Turney J: Evalua-CHr led to a significantly reduced need for intravenous
tion of RBC ferritin and reticulocyte measurements in monitoringiron, without any decrease in hematocrit or increase in
response to intravenous iron therapy. Am J Kidney Dis 30:814–
epoetin dose requirements. The superior performance 821, 1997
16. Dennison HA: Limitations of ferritin as a marker of anemia inof CHr might be explained by a far lower level of test
end stage renal disease. ANNA J 26:409–414, 1999variability compared to serum ferritin and transferrin satu-
17. Kumon Y, Suehiro T, Nishiya K, et al: Ferritin correlates with
ration. Finally, the use of monthly iron testing in both C-reactive protein and acute phase serum amyloid A in synovial
fluid, but not in serum. Amyloid 6:130–135, 1999groups led to hematocrit levels well above national aver-
18. Witte DL: Can serum ferritin be effectively interpreted in theages, without a need for excessively high epoetin doses.
presence of the acute-phase response? Clin Chem 37:484–485, 1991
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